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Nanomedicine on the move: from 
monotherapeutic regimens to 
combination therapies
“…besides reducing drug-related side effects (in 
monotherapeutic regimens), nanomedicine formulations also 
hold significant potential for improving the efficacy of systemic 
anticancer therapy (when integrated in rationally designed 
combination regimens).”
Significant progress has been made over the 
years in better understanding the molecu-
lar and pathophysiological principles of 
malignant transformation and tumori-
genesis. These improved insights into the 
etiology of cancer have led to the identifica-
tion of several novel and highly promising 
classes of anticancer therapeutics, such as 
growth factor receptor inhibitors, proteas-
ome inhibitors and anti-angiogenic agents. 
Given their ability to specifically interfere 
with certain hallmarks of cancer [1], these 
so-called molecularly targeted thera-
peutics, such as Herceptin® (Genentech), 
Erbitux® (ImClone LLC), Iressa® 
(AstraZeneca), Tarceva® (Astellas Pharma 
US, Inc.), Zolinza® (Merck & Co., Inc.), 
Avastin® (Genentech), Nexavar® (Onyx 
Pharmaceuticals) and Sutent® (Pfizer), are 
expected to hold significant potential for 
improving the balance between the efficacy 
and toxicity of systemically administered 
anticancer therapy. 
An important drawback that these 
second-generation anticancer agents share 
with their first-generation DNA-damaging 
counterparts, however, relates to their poor 
pharmacokinetic and biodistributional 
profile upon intravenous administration. 
Consequently, as is the case with stand-
ard chemotherapeutic drugs, they tend 
to be degraded and/or excreted relatively 
quickly, and they fail to efficiently localize 
to tumors over time. This, together with 
the fact that intravenously administered 
anticancer agents localize to and cause 
toxicity towards several different healthy 
tissues, limits their efficacy and their 
widespread use, and explains why only 
modest improvements have been made thus 
far in improving the therapeutic index of 
systemic anticancer therapy.
“...nanomedicine formulations 
aim to improve the balance 
between the efficacy and 
toxicity of systemic anticancer 
therapy.”
To overcome these shortcomings, at least 
to some extent, a large number of drug-
delivery systems have been designed and 
evaluated over the years [2,3]. These form-
ulations are currently routinely referred to 
as nanomedicines, and they include, for 
example, passively and actively targeted 
liposomes, polymers, micelles, proteins, 
dendrimers, nanotubes, nanospheres and 
nanoshells. As outlined in an article in 
this issue, these formulations primarily 
aim to assist anticancer agents in over-
coming some of the anatomical, physio-
logical, chemical and clinical barriers that 
drug molecules are confronted with upon 
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intra venous administration [4]. Examples of such barriers include 
low molecular weight, low stability, low solubility, large volume 
of distribution, renal excretion, hepatic degradation, cellular and 
nuclear membranes, the blood–brain barrier, drug efflux pumps, 
low cost–effectiveness and low time–effectiveness [5]. By assist-
ing drug molecules in overcoming some of these barriers, and 
thereby improving their pharmacokinetics, their biodistribution 
and their target site accumulation, nanomedicine formulations 
aim to improve the balance between the efficacy and the toxicity 
of systemic anticancer therapy.
In animal models, nanomedicines generally work very well: by 
means of their prolonged circulation kinetics and their ability to 
efficiently deliver drug molecules to tumors over time (via the 
enhanced permeability and retention effect [6]), they are generally 
able to improve both the efficacy and the tolerability of systemic 
drug therapy. In patients, on the other hand, nanomedicines are 
often only able to attenuate the toxicity of the intervention and 
they generally fail to improve the efficacy of the drug. This can be 
exemplified by taking into account that Doxil® (Janssen Products, 
LP) – PEGylated liposomal doxorubicin, arguably the most well-
known nanodrug – significantly reduces doxorubicin-related side 
effects (such as cardiomyopathy, bone marrow depression, alopecia 
and nausea), but in the majority of cases does not increase patient 
survival. Doxil only significantly improves therapeutic outcome 
in patients suffering from cisplatin-responsive ovarian carcinoma; 
in all other tumor types for which it is approved, such as in meta-
static breast cancer, multiple myeloma and Kaposi sarcoma, it only 
reduces the toxicity of intervention [2,3,5]. Analogously, Myocet® 
(Cephalon), which is non-PEGylated liposomal doxorubicin, also 
only affects the toxicity of systemic drug therapy: in a large Phase III 
trial in patients suffering from metastatic breast cancer, it reduced 
the incidence of cardiac events by more than half and the incidence 
of congestive heart failure by a factor of four, but its response rates 
and its progression-free survival times were comparable to those 
obtained for free doxorubicin. Similar observations have essentially 
been made for all other nanomedicine formulations evaluated in 
patients thus far, and polymers, proteins and micelles also gener-
ally do not improve the therapeutic index of systemic anticancer 
therapy by improving its efficacy, but by reducing its toxicity [2,3,5].
Based on these considerations, it seems tempting to argue that 
the formulations developed to date are simply not good enough. 
However, the picture is (much) more complicated, especially in the 
case of cancer, since many aspects of tumor biology and patho-
physiology are still not yet properly understood, while certain oth-
ers have been over- or mis-interpreted [3,7,8]. Examples of the latter 
include: the enhanced permeability and retention effect (the main 
driving force for passive drug targeting, which in patients turns 
out to be less prominent and less homogenous than in animal 
models); the poor tumor penetration of nano medicines (especially 
for formulations larger than ~10 nm); and the realization that 
active targeting to tumor cells does not lead to increases in tumor 
accumulation (and therefore is only advantageous in very specific 
cases, such as in the case of siRNA, which needs to be delivered 
into cells). Another important misconception relates to the clinical 
use of nanomedicine formulations. Especially in early-stage clinical 
trials, nano medicines are routinely used alone and are not embed-
ded in combination therapies. This is despite the widely accepted 
notion that malignancies need to be treated with more than one 
therapeutic modality in order to be effective and/or curative. 
Based on this reasoning, in the last few years, significant efforts 
have been invested into the development of treatment regimens 
in which nanomedicine formulations are used to improve the 
efficacy of combined-modality anticancer therapy [5,8–11]. These 
include studies in which they are combined with clinically rel-
evant fractionated radiotherapy, and in which they are used to 
simultaneously deliver multiple (chemo-)therapeutic drugs to 
tumors. 
“…many aspects of tumor biology and 
pathophysiology are still not yet properly 
understood, while certain others have been  
over- or mis-interpreted.”
Regarding radiotherapy, considering that the temporal and spa-
tial interaction between intravenously administered (bi- or tri-) 
weekly chemotherapy and clinically relevant daily radiotherapy is 
suboptimal, and that long-circulating and passively tumor -targeted 
drug-delivery systems are able to improve the temporal and spatial 
parameters of this interaction, we and others have convincingly 
demonstrated that nanomedicine formulations hold significant 
potential for improving the efficacy of radiochemotherapy. Initial 
proof-of-principle for this tumor-targeted combination regimen 
has been provided by Harrington and colleagues, who showed 
that animals treated with PEGylated liposomal doxorubicin (i.e., 
Doxil) in combination with both single-dose (4.5 and 9 Gy) and 
fractionated (3 × 3 Gy) radiotherapy survived significantly longer 
than animals treated with free doxorubicin plus single -dose and 
fractionated radiotherapy [12]. Similar findings were reported in 
the same study for PEGylated liposomal cisplatin [12]. Davies and 
coworkers confirmed this notion, showing not only that Doxil is 
more effective than free doxorubicin when combined with single-
dose (8 Gy) and with fractionated (3 × 3.6 Gy) radiotherapy, but 
also that radiotherapy improves the tumor accumulation and the 
intratumoral distribution of Doxil [13]. Li and colleagues reported 
similar findings for poly(glutamic acid)-bound paclitaxel (i.e., 
Opaxio™; Cell Therapeutics Inc.) [14], and also several of our own 
studies focusing on poly(N-[2-hydroxypropyl]-methacrylamide)-
bound doxorubicin and gemcitabine convincingly showed that 
radio therapy and carrier-based chemotherapy interact synergisti-
cally, with radiotherapy improving the tumor accumulation of 
nanomedicine formulations, and with nano medicine formulations 
improving both the efficacy and the toxicity of clinically relevant 
regimens of radiochemotherapy [15–18]. For Xyotax, early-stage 
clinical trials have convincingly confirmed the potential of ‘carrier-
based radiochemotherapy’, resulting in four complete and seven 
partial responses (with reductions in tumor volume of >50%) in 
12 patients suffering from advanced esophageal and gastric cancer 
[19]. Similar studies with other polymer–drug conjugates, as well 
as with liposomal, micellar and protein-based nanomedicines, are 
eagerly awaited. 
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Nanomedicine formulations have also been shown to be highly 
useful for improving the efficacy of chemotherapy combinations, 
in particular for delivering multiple (chemo-) therapeutic drugs 
to tumors simultaneously. Pioneering efforts in this regard have 
been reported by Mayer and coworkers, who co-loaded doxo-
rubicin and vincristine, irinotecan and floxuridine, and dauno-
rubicin and cytarabine into liposomes, and who optimized the 
ratios of the encapsulated agents, in order to achieve synergistic 
therapeutic responses [10]. Similarly promising results have been 
provided for polymer therapeutics by Vicent and colleagues and 
by us, co- conjugating doxorubicin and aminoglutethimide, and 
doxorubicin and gemcitabine to the same polymeric backbone, 
respectively, and showing that ‘polymer-based multidrug tar-
geting’ can lower the apoptosis threshold [20,21]. Analogously, 
Sengupta and coworkers prepared ‘temporally targeted’ nanopar-
ticles termed ‘NanoCells’ (consisting of a doxorubicin-containing 
poly[lactic-co-glycolic acid]-based core and a combrestatin-con-
taining phospholipid-poly[ethylene glycol]-based coating), and 
showed that the initial release of the antiangiogenic agent from 
the shell, followed by the subsequent release of the chemothera-
peutic agent from the core, resulted in synergistically improved 
anti-tumor responses [22]. Clinical proof-of-principle for using 
nanomedicine formulations for improving the efficacy of chem-
otherapy combinations has also already been provided by the 
people who pioneered this particular area of research (that is, by 
Mayer and colleagues) [10]. In two recent trials, they showed that 
liposomes co-loaded with daunorubicin and with cytarabine are 
able to achieve complete disease remission in approximately 25% 
of refractory leukemia patients, and that liposomes co-loaded 
with irinotecan and with floxuridine resulted in disease control 
in 11 out of 15 patients suffering from colorectal cancer [23,24]. 
These promising findings, together with the encouraging results 
obtained preclinically with the above and with a number of other 
two-drug-containing nanomedicine formulations, indicate that 
nanomedicines are highly suitable systems for improving the 
efficacy of chemotherapy combinations.
“Nanomedicine formulations have also been shown 
to be highly useful for improving the efficacy of 
chemotherapy combinations, in particular for 
delivering multiple (chemo-)therapeutic drugs to 
tumors simultaneously.”
Taken together, these insights convincingly demonstrate that 
besides reducing drug-related side effects (in monotherapeutic regi-
mens), nanomedicine formulations also hold significant potential 
for improving the efficacy of systemic anticancer therapy (when 
integrated in rationally designed combination regimens). This 
notion is in line with the results obtained for the majority of molec-
ularly targeted therapeutics, such as for Erbitux and Avastin, which 
are also only able to improve therapeutic outcome when com-
bined with radio- and/or chemo-therapy. Consequently, in addi-
tion to making more (and ever more advanced) nanomedicines, 
future studies should also focus on the development of novel and 
rational combination regimens, in order to fully exploit the bio-
compatibility and the beneficial biodistribution of nanomedicine 
formulations.
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